bioAffinity Technologies Publishes Clinical White Paper Highlighting Practical Use of CyPath® Lung for Pulmonary Nodule Risk Assessment
bioAffinity Technologies, Inc., a biotechnology company dedicated to advancing noninvasive diagnostics and early cancer detection, has announced the publication of a comprehensive clinical review and white paper that outlines a practical framework for incorporating its proprietary CyPath® Lung test into the evaluation and management of pulmonary nodules. Authored by the company’s Chief Medical Officer, Gordon H. Downie, M.D., Ph.D., the publication explores how CyPath® Lung can complement existing diagnostic approaches by providing clinicians with additional biologic information derived directly from the lung microenvironment.
The white paper, titled “Lung Nodules, Lung Microenvironment, Predictive Models and Clinician Risk Stratification Using CyPath® Lung Testing for Early Diagnosis of Lung Cancer,” addresses one of the most pressing challenges facing pulmonary medicine today: the increasing number of patients requiring evaluation for pulmonary nodules. As lung cancer screening programs expand worldwide, the widespread adoption of advanced imaging technologies, artificial intelligence-assisted detection, and long-term cancer surveillance has led to a substantial rise in the identification of lung nodules. Determining which nodules are likely to be malignant and which can be safely monitored remains a critical clinical challenge.
Addressing a Growing Diagnostic Challenge
The publication comes at a time when healthcare providers are managing an unprecedented volume of pulmonary nodule cases. Widespread implementation of low-dose computed tomography (LDCT) screening programs has significantly improved the early detection of lung abnormalities, particularly among individuals at high risk for lung cancer. At the same time, advances in imaging technology and AI-assisted radiology tools are identifying increasing numbers of incidental pulmonary nodules during scans performed for unrelated medical conditions.
While early detection has the potential to improve patient outcomes, it also presents new challenges. Many pulmonary nodules are benign, yet distinguishing them from early-stage lung cancers often requires multiple imaging studies, invasive biopsies, or surgical procedures. Existing predictive models provide valuable guidance but may not always offer sufficient certainty, particularly when imaging findings are ambiguous or conflicting.
The newly published white paper examines these challenges in detail and proposes an evidence-informed clinical framework for integrating CyPath® Lung into routine patient evaluation to enhance risk stratification.
Expanding Clinical Decision Support
Maria Zannes, President and Chief Executive Officer of bioAffinity Technologies, emphasized that physicians are increasingly seeking tools that can provide additional objective information when evaluating patients with pulmonary nodules.
She noted that pulmonary medicine is undergoing a significant transformation as clinicians encounter more pulmonary nodules than ever before. According to Zannes, the growing demand for improved risk assessment underscores the importance of technologies that can complement imaging studies and clinical judgment.
She explained that the white paper illustrates how CyPath® Lung can serve as an additional source of clinically meaningful information, helping physicians make more informed decisions regarding patient management. Rather than replacing existing diagnostic methods, the test is designed to support clinicians in determining which patients may require invasive diagnostic procedures and which individuals can safely continue with imaging surveillance.
Building on Three Years of Commercial Experience
The publication draws upon approximately three years of commercial experience since the introduction of CyPath® Lung into clinical practice. During this period, physicians have incorporated the noninvasive diagnostic test into pulmonary nodule evaluation across various healthcare settings.
According to the review, CyPath® Lung has demonstrated consistent clinical performance in assisting healthcare providers with malignancy risk assessment. The white paper includes multiple clinical case studies illustrating situations in which conventional imaging findings and existing predictive models alone produced uncertain or conflicting conclusions.
In these cases, the additional biologic information provided by CyPath® Lung helped physicians gain greater confidence in patient management decisions.
The publication highlights examples where the test contributed to improved diagnostic clarity by offering insights beyond what traditional imaging modalities alone could provide.
Understanding the Lung Microenvironment
A central focus of the white paper is the growing scientific understanding of the lung microenvironment and its potential role in early cancer detection.
Traditionally, many diagnostic approaches have relied on imaging or blood-based biomarkers to evaluate cancer risk. However, the lung represents a unique biological environment with localized immune activity, inflammatory responses, cellular interactions, and molecular changes that may not always be reflected in peripheral blood samples.
The publication explains that CyPath® Lung takes advantage of this concept by analyzing sputum collected directly from the lungs rather than relying on circulating blood biomarkers.
Because sputum originates from the respiratory tract, it contains cellular material and biologic signals that more directly reflect processes occurring within the lung itself.
By evaluating this material, clinicians may gain access to additional information regarding local inflammatory responses, genetic alterations, and early tumor-associated changes.
A Different Diagnostic Approach
Unlike conventional blood-based liquid biopsy technologies that assess circulating biomarkers, CyPath® Lung focuses on material collected directly from the lungs through a noninvasive sputum sample.
The test combines several advanced technologies to evaluate the sample, including:
- Proprietary flow cytometry
- Artificial intelligence-assisted analysis
- Porphyrin-based labeling of malignant cells
- Quantitative assessment of cellular characteristics
This integrated analytical approach is designed to identify biologic patterns associated with malignancy while providing objective information that complements imaging findings.
According to the publication, evaluating the lung microenvironment offers clinicians an additional perspective when conventional diagnostic methods yield inconclusive results.
Reviewing Existing Predictive Models
The white paper also provides a comprehensive review of currently available pulmonary nodule risk prediction models.
These models often incorporate variables such as:
- Patient age
- Smoking history
- Nodule size
- Nodule morphology
- Growth rate
- Imaging characteristics
- Clinical history
While these predictive tools have become valuable components of pulmonary medicine, the publication emphasizes that each possesses inherent limitations.
Risk prediction models generate statistical probabilities rather than definitive diagnoses, and their accuracy can vary depending on patient populations and individual clinical circumstances.
The review argues that no single diagnostic method should be used in isolation.
Instead, effective pulmonary nodule evaluation should incorporate multiple complementary sources of information, including imaging, clinical judgment, patient history, predictive models, and biologic testing.
Specialty-Specific Clinical Pathways
One of the primary objectives of the publication is to provide practical guidance for integrating CyPath® Lung into different clinical environments.
The white paper proposes specialty-specific clinical pathways for three primary healthcare settings.
Primary Care
Primary care physicians increasingly encounter pulmonary nodules identified incidentally during imaging performed for unrelated reasons.
In these situations, clinicians often face difficult decisions regarding referral, additional testing, or observation.
The publication discusses how CyPath® Lung may provide additional risk stratification information that supports referral decisions and follow-up planning.
Pulmonary Nodule Clinics
Pulmonary specialists and interventional pulmonologists frequently evaluate patients being considered for bronchoscopy, needle biopsy, or surgical intervention.
The white paper examines how integrating CyPath® Lung into existing evaluation protocols may help refine malignancy risk assessment before invasive diagnostic procedures are performed.
Oncology Surveillance
Cancer survivors often undergo long-term imaging surveillance following treatment.
Distinguishing recurrent malignancy from treatment-related changes or benign abnormalities can be clinically challenging.
The publication suggests that CyPath® Lung may offer valuable biologic information that complements surveillance imaging and assists clinicians in evaluating suspicious findings during follow-up care.
Supporting, Not Replacing, Clinical Judgment
Dr. Gordon Downie emphasizes throughout the publication that CyPath® Lung is not intended to replace physician expertise or established clinical guidelines.
Instead, the technology is designed to function as an additional diagnostic resource that can provide objective biologic information when conventional findings remain uncertain.
He explains that every patient presents a unique clinical picture, making individualized evaluation essential.
According to Dr. Downie, the goal is to supplement clinician judgment by adding another layer of information, particularly in situations where imaging studies, predictive models, and clinical findings may not align.
The lung microenvironment offers insights that have historically been unavailable through traditional imaging or blood-based diagnostic testing alone.
The Science Behind Lung Microenvironment Analysis
The publication discusses increasing scientific recognition that the lung possesses its own highly specialized biological ecosystem.
Local immune responses, inflammatory activity, genetic alterations, and tumor-associated molecular changes occur within this environment and may provide important clues regarding disease progression.
CyPath® Lung is designed to evaluate these biologic processes directly.
The test analyzes sputum samples using proprietary laboratory methods that identify porphyrin-labeled malignant cells while simultaneously applying advanced flow cytometry and artificial intelligence algorithms to characterize cellular populations.
This multidimensional analysis aims to provide clinicians with objective data reflecting ongoing biologic activity within the lungs.
Potential Impact on Patient Care
Improved risk stratification has important implications for both patients and healthcare systems.
More accurate assessment of pulmonary nodules may help reduce unnecessary invasive procedures for individuals with benign disease while facilitating earlier intervention for patients with malignant lesions.
By providing additional biologic information, CyPath® Lung has the potential to support more personalized patient management decisions, optimize surveillance strategies, and improve diagnostic confidence across multiple clinical settings.
The white paper suggests that incorporating biologic data from the lung microenvironment alongside imaging and established predictive models may contribute to a more comprehensive understanding of individual patient risk.
As lung cancer screening programs continue to expand and advances in imaging technology detect increasing numbers of pulmonary nodules, clinicians face growing pressure to accurately distinguish benign findings from early-stage malignancies. The publication of this comprehensive white paper represents bioAffinity Technologies’ effort to provide healthcare professionals with practical guidance for integrating CyPath® Lung into routine clinical practice.
Drawing on three years of commercial experience, current scientific understanding of the lung microenvironment, and real-world clinical case studies, the publication outlines how CyPath® Lung can complement existing diagnostic tools by providing additional biologic information from sputum samples collected directly from the lungs. Rather than replacing established guidelines or physician expertise, the proposed framework positions CyPath® Lung as an important adjunctive tool that may enhance risk stratification, improve clinical decision-making, and support more personalized management of patients undergoing pulmonary nodule evaluation and lung cancer surveillance.
About CyPath® Lung
CyPath® Lung by bioAffinity Technologies is a noninvasive test designed to improve the early detection of lung cancer in patients at high risk for the disease. CyPath® Lung uses advanced flow cytometry and proprietary artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells.
In a published clinical trial of high-risk patients, CyPath® Lung demonstrated 92% sensitivity, 87% specificity, 88% accuracy and 99% negative predictive value (NPV) in detecting lung cancer in patients at high risk for the disease who had small indeterminate lung nodules less than 20 millimeters. The high NPV gives physicians greater confidence that a negative result is truly negative, potentially sparing patients from unnecessary invasive and costly procedures. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) and is not intended for use as a sole diagnostic tool and should be considered alongside other clinical findings.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer.
CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. LDTs are overseen under the Clinical Laboratory Improvement Amendments (CLIA), which are administered by the Centers for Medicare & Medicaid Services. For more information, visit www.bioaffinitytech.com.